Skip to main content
    P

    Predictive Oncology Inc (POAI)

    Official site

    HEALTH INFORMATION SERVICES

    $7.71
    -0.27 (-3.38%)

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Predictive Oncology Inc (POAI) Financials: Revenue, Profit and Cash Flow

    Updated Nov 14, 2025. Financial statements from company filings, amounts in US dollars.

    Predictive Oncology reported revenue of $1.62M for the fiscal year ended Dec 31, 2024, down 0.2% from the year before. That year, net income was -$12.20M with a net margin of -751.4%, operating cash flow was -$11.96M and free cash flow was -$11.97M. The quarter ended Sep 30, 2025 had revenue of $3.62K.

    Revenue and Margins

    Over the 9 years to Dec 2024, revenue grew from $654.35K, a compound annual rate of 10.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$1.62M-0.2%49.1%-673.7%-751.4%
    Dec 2023$1.63M+8.1%62.6%-744.5%-859.1%
    Dec 2022$1.51M+6.0%66.4%-1729.3%-1709.6%
    Dec 2021$1.42M+13.4%65.7%-1437.9%-1383.6%
    Dec 2020$1.25M-11.3%64.3%-996.9%-2067.0%
    Dec 2019$1.41M0.0%62.3%-975.8%-1373.7%
    Dec 2018$1.41M+115.6%70.5%-556.9%-714.5%
    Dec 2017$654.84K+43.4%77.4%-1183.0%-1183.0%
    Dec 2016$456.50K-30.2%60.2%-1429.6%-1429.6%
    Dec 2015$654.35KN/A53.5%-672.4%-732.1%
    Annual, fiscal years ended Dec 2015 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss narrowed from the year before.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Revenue$1.62M$1.63M$1.51M$1.42M$1.25M$1.41M$1.41M$654.84K$456.50K$654.35K
    Cost of revenue$826.14K$609.21K$505.11K$487.02K$447.19K$531.81K$415.76K$148.04K$181.62K$303.98K
    Gross profit$797.68K$1.02M$1.00M$933.66K$805.08K$879.75K$995.89K$506.79K$274.88K$350.37K
    Research and development$25.99K$122.31K$320.32K$315.85K$2.35M$2.96M$1.86M$289.00K$406.00K$261.00K
    Operating income-$10.94M-$12.12M-$26.03M-$20.43M-$12.48M-$13.77M-$7.86M-$7.75M-$6.53M-$4.40M
    Net income-$12.20M-$13.98M-$25.74M-$19.66M-$25.88M-$19.39M-$10.09M-$7.75M-$6.53M-$4.79M
    EBITDA-$10.24MN/A-$13.95M-$12.13M-$11.46M-$12.41M-$7.71M-$5.98M-$6.44M-$4.32M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$3.62K$2.68K$110.31K$611.59K$345.69K$278.72K$419.65K$335.03K$676.63K$490.11K$239.90K$363.47K
    Gross profit-$4.74K-$185.79K$65.19K$320.96K$148.77K$125.75K$69.67K-$71.26K$578.76K$330.35K$119.76K$210.03K
    Operating income-$77.65M-$2.66M-$2.29M-$2.12M-$2.31M-$3.19M-$4.24M-$3.51M-$2.74M-$3.96M-$3.46M-$4.43M
    Net incomeN/A-$2.07M-$2.44M-$2.17M-$3.09M-$3.18M-$4.22M-$3.48M-$3.16M-$3.92M-$4.26M-$22.26M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents of $734.67K were 14.8% of total assets of $4.97M, against total liabilities of $5.18M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Total assets$4.97M$14.42M$25.73M$43.77M$13.06M$22.38M$3.71M$3.62M$2.81M$5.63M
    Current assets$2.23M$10.08M$23.36M$29.46M$1.51M$798.26K$1.45M$2.37M$2.61M$5.40M
    Cash and equivalents$734.67K$8.73M$22.07M$28.20M$678.33K$150.83K$162.15K$766.19K$1.76M$4.86M
    Total liabilities$5.18M$6.15M$3.97M$3.51M$10.42M$11.14M$3.66M$932.34K$1.88M$1.52M
    Shareholder equity-$202.61K$8.27M$21.77M$40.27M$2.64M$11.23M$53.47K$2.69M$923.68K$4.11M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$3.14M$3.44M$5.87M$4.97M$7.50M$10.59M$10.60M$14.42M$18.17M$20.97M$25.06M$25.73M
    Total liabilities$80.57M$5.09M$6.01M$5.18M$5.53M$6.49M$6.55M$6.15M$6.52M$6.26M$6.51M$3.97M
    Cash and equivalents$181.67K$506.08K$3.09M$734.67K$3.08M$5.33M$5.20M$8.73M$11.92M$14.76M$18.60M$22.07M
    Shareholder equity-$77.43M-$1.65M-$145.80K-$202.61K$1.97M$4.09M$4.05M$8.27M$11.65M$14.71M$18.55M$21.77M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Operating cash flow-$11.96M-$13.19M-$12.37M-$12.21M-$12.26M-$8.73M-$5.29M-$4.46M-$4.38M-$7.49M
    Capital expenditures$9.51K$21.53K$475.70K$962.32K$360.78K$26.61K$232.00K$55.27K$44.75K$60.56K
    Free cash flow-$11.97M-$13.21M-$12.85M-$13.17M-$12.62M-$8.76M-$5.52M-$4.52M-$4.43M-$7.55M
    Dividends paidN/A$794N/A$4.51M$2.96BN/AN/AN/AN/AN/A
    Investing cash flow$22.49K-$302.37K-$475.70K-$10.61M-$167.46K-$599.09K-$1.11M-$1.65M-$422.86K-$60.56K
    Financing cash flow$3.94M$148.90K$6.72M$50.34M$12.95M$9.32M$5.79M$5.11M$1.71M$12.39M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$1.65M-$3.32M-$756.35K-$3.04M-$2.28M-$3.22M-$3.42M-$3.08M-$3.10M-$3.57M-$3.43M-$3.23M
    Capital expenditures$3$0$0$0$3$6.48K$3.03K$7.29K$3.92K$259.10K$46.64K$63.60K
    Free cash flow-$1.65M-$3.32M-$756.35K-$3.04M-$2.28M-$3.22M-$3.42M-$3.09M-$3.11M-$3.83M-$3.47M-$3.30M
    Last 12 quarters

    Frequently Asked Questions About POAI

    What is Predictive Oncology's annual revenue?

    Predictive Oncology reported revenue of $1.62M for the fiscal year ended Dec 31, 2024.

    How fast is Predictive Oncology's revenue growing?

    Revenue was down 0.2% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was 4.6%.

    Is Predictive Oncology profitable?

    No. Predictive Oncology reported net income of -$12.20M for the fiscal year ended Dec 31, 2024, with a net margin of -751.4%.

    How much free cash flow does POAI generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$11.96M minus capital expenditures of $9.51K produced free cash flow of -$11.97M.

    How much debt does Predictive Oncology have?

    The balance sheet dated Dec 31, 2024 reported cash and equivalents of $734.67K.